The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index ("underlying index"). The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in Chinaâs biotechnology industry. It is non-diversified.
IPO Year: n/a
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Fastest customizable press release news feed in the world
NEW YORK, Jan. 19, 2024 /PRNewswire/ -- Global X ETFs, the New York-based provider of exchange-traded funds, today announced the scheduled liquidation of the following ETFs (the "Funds"), based on an ongoing review process of its product lineup to ensure it meets the evolving needs of its clients. The Funds scheduled for liquidation include: Fund Ticker CUSIP Global X Cannabis ETF POTX 37954Y145 Global X Carbon Credits Strategy ETF NTRL 37960A586 Global X China Biotech Innovation ETF CHB 37954Y251 Global X Green Building ETF GRNR 37960A842 Global X Health & Wellness ETF BFIT 3